Data Monitoring Should Be Tailored To Device Trial Needs – Manufacturers
This article was originally published in The Gray Sheet
Executive Summary
FDA's guidance on clinical trial data monitoring committees (DMCs) should make clear that device firms need not hire independent statisticians to perform interim analyses, Medtronic writes in Feb. 15 comments to FDA regarding the November 2001 draft guidance